Q-omics provides the consensus-scored NTRK3 profile across patient tissues and cancer cell-line models. NTRK3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NTRK3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, NTRK3 RNA expression shows 20,107 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where NTRK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTRK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTRK3 survival associations across molecular data types. NTRK3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTRK3 RNA expression–survival associations across cancer types. High NTRK3 expression shows unfavorable associations in KIRP, UVM, BLCA and LUSC, but favorable associations in BRCA and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for NTRK3 RNA expression.
This table summarizes NTRK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NTRK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTRK3 shows lower tumor expression in KICH, BLCA, COAD, LUAD, LUSC and KIRC. The KICH box plot shows higher NTRK3 RNA expression in normal versus tumor tissue (log2 FC = −0.933, t-test p < 0.001).
This table shows molecular features associated with NTRK3 in patient tissues and cancer cell lines. In patient samples, NTRK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTRK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
